Tag: MDD adjunctive therapy ranking
New Meta-Analysis Ranks CAPLYTA®️ Lumateperone First in Efficacy and Metabolic Safety for Adjunctive MDD Treatment
Intra-Cellular Therapies, Inc. announced the presentation of a new network meta-analysis (NMA) demonstrating that CAPLYTA® (lumateperone) showed the greatest improvement across four key efficacy outcomes among...